Shares of Silence Therapeutics plc (LON:SLN – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 535 ($6.80) and traded as high as GBX 546 ($6.94). Silence Therapeutics shares last traded at GBX 535 ($6.80), with a volume of 913,528 shares trading hands.
Silence Therapeutics Stock Performance
The firm has a market capitalization of £480.35 million and a price-to-earnings ratio of -11.01. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.36 and a current ratio of 4.52. The stock’s fifty day moving average is GBX 535 and its two-hundred day moving average is GBX 535.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Recommended Stories
- Five stocks we like better than Silence Therapeutics
- Conference Calls and Individual Investors
- MarketBeat Week in Review – 5/20 – 5/24
- Why Invest in Biotech Stocks
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- Using the MarketBeat Dividend Tax Calculator
- These 2 Retail Traders Favorites are Nearing Major Breakouts
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
